8-K filing — BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
Filed: 2026-08-14 AccNo: 0001104659-26-097180 Size: 281 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY
Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.35) per share. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year.
Stock Market: Will S&P 500 Open Up or Down Today?
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.
Lunai Bioworks shares are trading lower after the company announced it filed for a non-timely 10-K with the U.S. SEC and anticipates reporting a net loss for the fiscal year ended June 30, 2026, of approximately $3.2 million.
Lunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2M
Lunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation Platform
The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular